Search

everythinglearnresearchcommunity

for

Search:↓

The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.

Too much male hormone is the main cause of Polycystic Ovary Syndrome.

TGF-β1 from dermal papilla cells suppresses hair growth, and targeting it may help treat androgenetic alopecia.

miR-218-5p helps skin and hair growth by targeting SFRP2 and activating a specific signaling pathway.

Most patients improved with oral contraceptives, but some needed additional treatment.

A woman's rare adrenal tumor caused high testosterone and cortisol levels, which normalized after the tumor was removed.

Chrousos Syndrome is caused by mutations that make the body less sensitive to glucocorticoids, leading to various symptoms and requiring high-dose treatment.

The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.

The document suggests creating a validated score to diagnose Cushing's Syndrome and considers plasma steroid profiling as a simpler diagnostic method.

Using neurohormones to control keratin can lead to new skin disease treatments.

The conclusion is that effective cancer treatment often requires a combination of therapies, but must be carefully managed due to serious side effects and the risk of immunosuppression.

Accurate quantitative bioanalysis using LC-MS/MS is challenging due to matrix effects, but using internal standards and new methods like in-sample calibration could improve results.

Activating TRPV3 stops human hair growth.

Increasing mir-302 turns human hair cells into stem cells by changing gene regulation and demethylation.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Androgens may cause hair loss by increasing TGF-beta1 from scalp cells, which inhibits hair cell growth.

Male pattern baldness involves hormones and cell signals affecting hair growth.

Notch/CSL signaling controls hair follicle differentiation through Wnt5a and FoxN1.

The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.

The S100A4 protein is more common in psoriatic skin and could be a target for treating psoriasis.

Apigenin may help promote hair growth and could treat hair loss.

Different sPLA2 enzymes affect immunity, skin and hair health, reproduction, and may be potential targets for therapy.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

Modified KGF mRNA helps skin cells grow and move faster, which may improve wound healing.

Porphyra-334 may help reduce wrinkles and promote hair growth.

6-Gingerol from ginger may slow down hair growth by affecting certain enzymes and growth factors.

New testosterone analogs show promise for male contraception with better activity and potentially fewer side effects.

KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.

The document describes a way to measure biotin in blood to prevent wrong test results in hormone level testing.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.